Seres Therapeutics/$MCRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Ticker
$MCRB
Sector
Primary listing
Employees
66
Headquarters
Website
MCRB Metrics
BasicAdvanced
$74m
-
-$5.17
0.12
-
Price and volume
Market cap
$74m
Beta
0.12
52-week high
$29.98
52-week low
$6.56
Average daily volume
50k
Financial strength
Current ratio
1.646
Quick ratio
1.554
Long term debt to equity
262.78
Total debt to equity
303.781
Profitability
EBITDA (TTM)
-83.804
Gross margin (TTM)
-5,590.67%
Net profit margin (TTM)
-4,088.84%
Operating margin (TTM)
-7,640.98%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-38.88%
Return on equity (TTM)
-121.87%
Valuation
Price to revenue (TTM)
60.077
Price to book
2.75
Price to tangible book (TTM)
2.75
Price to free cash flow (TTM)
-1.626
Free cash flow yield (TTM)
-61.49%
Free cash flow per share (TTM)
-4.667
Growth
Earnings per share change (TTM)
-157.67%
3-year revenue growth (CAGR)
-39.24%
10-year revenue growth (CAGR)
-8.24%
3-year earnings per share growth (CAGR)
-51.55%
10-year earnings per share growth (CAGR)
-18.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $74M as of May 19, 2026.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0 as of May 19, 2026.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of May 19, 2026.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.